Core Insights - Lumexa Imaging reported strong financial results for Q4 2025, highlighting growth in outpatient imaging services and a positive outlook for 2026 [2][4] Financial Performance - Consolidated revenues for Q4 2025 reached $267.7 million, a 7.9% increase from $248.0 million in Q4 2024 [4] - Adjusted EBITDA for Q4 2025 was $63.8 million, up 18.6% from $53.7 million in Q4 2024, with an Adjusted EBITDA margin of 23.8% [4] - The company experienced a net loss of $28.7 million in Q4 2025, compared to a net loss of $25.1 million in Q4 2024 [4] - For the full year 2025, consolidated revenues totaled $1.023 billion, a 7.8% increase from $948.9 million in 2024 [4] - Adjusted EBITDA for the full year 2025 was $230.2 million, a 14.6% increase from $200.8 million in 2024 [4] Operational Highlights - Lumexa Imaging performed a total of 2,418,096 outpatient procedures in 2025, a 4.6% increase from 2,312,645 in 2024 [3] - Advanced procedures accounted for 30.1% of total procedures in 2025, up from 29.2% in 2024 [3] - The company opened a record number of de novo centers in 2025, contributing to its growth strategy [2] Future Outlook - Lumexa Imaging reiterated its guidance for 2026, expecting revenues between $1.045 billion and $1.097 billion and Adjusted EBITDA between $234 million and $242 million [6][11] - The company anticipates continued growth and margin expansion driven by strong demand for outpatient care and a focused strategy on same-center growth and geographic expansion [2]
Lumexa Imaging Announces Fourth Quarter and Full Year 2025 Results, Reiterates Full Year 2026 Guidance